Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence
|
|
- Lambert Bates
- 5 years ago
- Views:
Transcription
1 16th Annual MCI Symposium January 20, 2018 Miami, FL Neuropsychiatric symptoms as predictors of MCI and dementia: Epidemiologic evidence Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic, Scottsdale, Arizona 2015 MFMER slide-1
2 Conflict of interest Dr Geda served as an advisory board member to Lundbeck in March of Dr Geda is funded by the European Union, NIH and the Edward and Lili foundation (Hague, the Netherlands) 2015 MFMER slide-2
3 Outline Introduction: Neuropsychiatric symptoms (NPS), MCI and dementia Study 1: From normal aging to incident MCI as predicted by baseline NPS (Geda et al. Am J Psychiatry. 2014) Study 2: From MCI to incident dementia as predicted by baseline NPS (Pink et al., Neurology. 2015) NPS and neuroimaging biomarkers of presymptomatic AD 2015 MFMER slide-3
4 Introduction: NPS, MCI and dementia Neuropsychiatric symptoms (NPS) are highly prevalent in patients with MCI (Lyketsos, JAMA 2002; Geda, Arch Gen Psychiatry 2008) Prevalence of NPS in MCI ranges from 35% - 85% (Monastero, J Alzheimers Dis 2009; Review) Most common NPS are apathy, depression, and irritability in both Cardiovascular Health Study (Lyketsos, JAMA 2002) and Mayo Clinic Study of Aging (Geda, Arch Gen Psychiatry 2008) 2015 MFMER slide-4
5 Population-based indices of depression Author Study Sample size/age Prevalence/Frequency Lyketsos et al., 2002 Geda et al., 2008 Lyketsos et al., 2000 Steffens et al., 2000 Okura et al., 2010 Chan et al., 2003 Luppa et al., 2011 Cardiovascular Health Study Mayo Clinic Study of Aging 320 MCI, 362 dementia, 65 yrs 329 MCI, 1640 CN, 70 yrs Cache County Study 673 no dementia, 329 dementia, 65 yrs Cache County Study Aging, Demographics & Memory Study Memory and Medical Care Study, MD, USA Leipzig Study of the Aged, GER 4559 no dementia, 65 yrs 20.1% (MCI), 32.3% (dementia) 27.0% (MCI), 11.4% (CN) 7.0% (CN), 23.7% (dementia) Point prevalence: 5.3% Lifetime prevalence: 15.8% 856, 71 yrs 12% (CN), 30% (CIND), 25% (dementia) 121 MCI, 333 dementia 1006, 75 yrs 38.2% 15.7% (MCI), 21.9% (dementia) 2015 MFMER slide-5
6 Depression predicting CN to imci Steenland et al., 2012 (NACC) 1 Richard et al., 2013 (North Manhattan) Geda et al., 2014 (MCSA) Geda et al., 2006 (MCSA) Goveas et al., 2011 (Womens Health) Dotson et al., 2010 (BLSA) Wilson et al., 2007 Panza et al., 2008 (Italian Study on Aging) Relative Risk Hazard Ratio 2015 MFMER slide-6
7 Depression predicting MCI to idementia/ iad Rosenberg et al., 2013 (NACC) 1 Van der Mussele et al., 2014 (Belgium) 2 Pink et al., 2015 (MCSA) Goveas et al., 2011 (Womens Health) Dotson et al., 2010 (BLSA) Devanand et al., 1996 (North Manhattan) Panza et al., 2008 (Italian Study on Aging) Modrego et al., 2004 Palmer et al., Relative Risk Hazard Ratio 1 GDS > 0; 2 GDS MFMER slide-7
8 Potential mechanisms linking NPS with MCI/ dementia Etiologic pathway NPS Unknown mechanisms MCI Shared risk factor/ confounding Amyloid deposition NPS MCI Reverse causality Neuropathological changes MCI NPS Interaction Amyloid deposition Interaction MCI NPS Adapted from Geda et al., Alzheimers Dement Sep;9(5): MFMER slide-8
9 Study Setting Prospective cohort study derived from the populationbased Mayo Clinic Study of Aging in Olmsted County, MN PI: Dr. Ronald C. Petersen (Roberts, Geda et al., 2008) MN WI IA Olmsted County Rochester, MN 2015 MFMER slide-9
10 Methods Classification of normal cognitive aging, MCI, and dementia adjudicated by an expert consensus panel based on published criteria after reviewing neurologic, cognitive, and other pertinent data Hazard ratios (HR) and 95% confidence intervals (95% CI) were computed using Cox proportional hazards model, with age as a time scale NPS at baseline : measured by Neuropsychiatric Inventory Questionnaire (NPI-Q) 2015 MFMER slide-10
11 Study 1: Objective Prospective cohort study to estimate the risk of incident mild cognitive impairment (MCI) in cognitively normal elderly (aged 70 years) individuals, with or without neuropsychiatric symptoms (NPS) at baseline 2015 MFMER slide-11
12 Design: Prospective cohort study CN + NPS Incident MCI No incident MCI CN N = 1587 CN - NPS Incident MCI No incident MCI Median follow up time = 5.0 years [3.8, 5.3] 2015 MFMER slide-12
13 2015 MFMER slide-13
14 2015 MFMER slide-14
15 Conclusion HR for hippocampal volume in predicting incident MCI is 1.8 (95% CI= ) (Kantarci et al., 2013) HR for apathy in predicting incident MCI is 2.26 (95% CI= ) and 3.06 for agitation (95% CI= ) Difference in strength of predicting incident MCI by biomarker compared to NPS cannot be attributed to methodological difference (both research took place in the context of MCSA) Risk of incident MCI by baseline NPS was as strong as or stronger than risk predicted by APOEε4, medical comorbidities, or demographic variables (e.g., low education) 2015 MFMER slide-15
16 Study 2: Objective To investigate the population-based interaction between a biological variable (APOEε4), NPS, and the risk of incident dementia among subjects with prevalent MCI 2015 MFMER slide-16
17 Design: Prospective cohort study MCI + NPS N = 71 Incident dementia No incident dementia Prevalent MCI N = 275 MCI NPS N = 204 Incident dementia No incident dementia Median follow up time = 2.8 years [1.1, 4.8] 2015 MFMER slide-17
18 2015 MFMER slide-18
19 2015 MFMER slide-19
20 Interaction between NPS, APOEε4 and incident dementia 2015 MFMER slide-20
21 Conclusion NPS (depression, apathy, agitation) significantly predict progression from prevalent MCI to incident dementia Synergistic interaction between depression or apathy and APOE ε4 in further elevating the risk of incident dementia NPS may thus be useful clinical markers and clinicians may want to conduct a thorough evaluation looking for NPS If and when an NPS is identified then treatment may be warranted 2015 MFMER slide-21
22 NPS and neuroimaging biomarkers of presymptomatic AD Our team has reported cross-sectional associations between anxiety symptoms with reduced global cortical thickness and reduced thickness of the frontal and temporal cortex as measured by MRI (Pink et al., 2016) depressive and anxiety symptoms with an abnormal FDG-PET, and the point estimate is even higher for APOE ɛ4 carriers (Krell-Roesch et al., 2016) depression and anxiety with an abnormal PiB-PET (Krell- Roesch et al., in press) 2015 MFMER slide-22
23 Theoretical model linking NPS with AD biomarkers and cognitive outcomes β-amyloid Neurodegeneration NPS Cognition Incident MCI/ dementia Strong evidence Less evidence Geda et al American Journal of Geriatric Psychiatry 2015 MFMER slide-23
24 Acknowledgement Janina Krell-Roesch, PhD and members of the Geda lab at Mayo Clinic Scottsdale, AZ Colleagues and co-investigators from the Mayo Clinic Study of Aging in Rochester, MN Funding sources: NIA grants AG06786, K01 AG028573; NIMH grant K01 MH68351; National Center for Research Resources grant RR (Mayo Clinic CTSA [Career Transition Award]); RWJ Foundation (Harold Amos); Project no. LQ1605 from the National Program of Sustainability II (MEYS CR); Robert H. and Clarice Smith and Abigail Van Buren Alzheimer s Disease Research Program; Edli Foundation 2015 MFMER slide-24
Mild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationMild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm?
Mild Behavioral Impairment (MBI): Symptoms, Prodrome, or False Alarm? Constantine G. Lyketsos, MD, MHS Chair of Psychiatry, Johns Hopkins Bayview Elizabeth Plank Althouse Professor, Johns Hopkins University
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationOscar L. Lopez, M.D. Departments of Neurology and Psychiatry Alzheimer s Disease Research Center University of Pittsburgh School of Medicine
14th Annual Mild Cognitive Impairment Symposium The Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center Miami, Florida Markers of inflammation and immune activation, small
More informationAnxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?
The 2016 Annual Public Educational Forum Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links? Mary Ganguli MD MPH Professor of Psychiatry, Neurology, and Epidemiology, University of
More informationORIGINAL ARTICLE. Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Normal Cognitive Aging. normal cognitive aging
ORIGINAL ARTICLE Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Normal Cognitive Aging Population-Based Study Yonas E. Geda, MD, MSc; Rosebud O. Roberts, MB, ChB, MS; David S.
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More informationAlzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT
Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationSHARED CARE OF MCI/EARLY DEMENTIA
SHARED CARE OF MCI/EARLY DEMENTIA BY DR. OLUFEMI BANJO MD, DTM, DCP, DIPA&DS, DHM, M.Med.Sc, FRCP(C) GERIATRIC PSYCHIATRIST. ASSISTANT MEDICAL DIRECTOR, ADULT MENTAL HEALTH AND ADDICTION, GRAND RIVER HOSPITAL
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationRecent publications using the NACC Database. Lilah Besser
Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationDepression: An Important Risk Factor for Cognitive Decline
Depression: An Important Risk Factor for Cognitive Decline No conflicts of interest Sarah K. Tighe, M.D. Assistant Professor University of Iowa Carver College of Medicine Department of Psychiatry Institute
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationAlzheimer s Disease Neuroimaging Initiative
Alzheimer s Disease Neuroimaging Initiative Steering Committee Meeting April 18, 2016 Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Table 1. Participants Autopsied
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationPractical Matters in the Care of A Person with Dementia
Practical Matters in the Care of A Person with Dementia 7 th Annual Neurology Update for Primary Care Deborah S. Hoffnung, PhD, ABPP CN November 16, 2018 1 Typical Aging, MCI/CIND, dementia Common Dementia
More informationNIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2013 May 01.
NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2012 May ; 69(5): 614 622. doi:10.1001/archneurol.2011.3029. Comparison of imaging biomarkers in ADNI versus the Mayo
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationThe course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY Int J Geriatr Psychiatry 2005; 20: 531 536. Published online in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/gps.1317 The course of neuropsychiatric
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationResearch Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect of Apolipoprotein E ε4 Status
Behavioural Neurology Volume 2015, Article ID 275256, 6 pages http://dx.doi.org/10.1155/2015/275256 Research Article Sex Differences in Neuropsychiatric Symptoms of Alzheimer s Disease: The Modifying Effect
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationUnequal Burden and Unparalleled Opportunities: Minorities in Alzheimer s Disease Research
Unequal Burden and Unparalleled Opportunities: Minorities in Alzheimer s Disease Research J Taylor Harden, PhD, RN Executive Director National Hartford Centers of Gerontological Nursing Excellence Agenda
More informationClinical Genetics & Dementia
Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer Nayana.lahiri@nhs.net Aims of the Session To appreciate the potential utility of family history
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationNIH Public Access Author Manuscript Dement Geriatr Cogn Disord. Author manuscript; available in PMC 2013 August 28.
NIH Public Access Author Manuscript Published in final edited form as: Dement Geriatr Cogn Disord. 2012 ; 34(2): 96 111. doi:10.1159/000342119. Neuropsychiatric symptoms and global functional impairment
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationHHS Public Access Author manuscript Am J Geriatr Psychiatry. Author manuscript; available in PMC 2017 January 01.
Trajectories of neuropsychiatric symptoms and cognitive decline in mild cognitive impairment Nicholas D. David, B.A. 1,*, Feng Lin, R.N., Ph.D. 1,2,*, and Anton P. Porsteinsson, M.D. 1, for the Alzheimer
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationThe Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD
The Role of Cognitive Reserve in the clinical presentation of Alzheimer s Disease Dorene M. Rentz, PsyD Division of Cognitive and Behavioral Neurology, Brigham and Women s Hospital Co-Director of the Center
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationThe place for treatments of associated neuropsychiatric and other symptoms
The place for treatments of associated neuropsychiatric and other symptoms Luca Pani dg@aifa.gov.it London, 25 th November 2014 Workshop on Alzheimer s Disease European Medicines Agency London, UK Public
More informationFirst US Plan to Address Alzheimer s Disease
First US Plan to Address Alzheimer s Disease Ronald C. Petersen, PhD, MD Chair Advisory Council on Research, Care and Services for the National Alzheimer s Project Act 2012 MFMER 3205603-1 NAPA Advisory
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationPositioning. > MEMENTO is a large observational study enrolling patients at an. Data first availability for project analyses
: determinants and Evolution of AlzheiMer s disease and related disorders ITMO Santé publique OVERVIEW AT A GLANCE Bordeaux Geneviève Chêne, MD, PhD Professor of Biostatistics and Public Health, Bordeaux
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationSUPPLEMENTARY INFORMATION In format provided by Frank et al. (JULY 2010)
Table 1 Imaging bios for Alzheimer s Visual rating High correlation with Multicenter studies have Accuracy for longitudinal hippocampus volume (R 2 been performed, but changes only at chance about 0.9,
More information2013 AAIC WW-ADNI Meeting, Boston K-ADNI Update
2013 AAIC WW-ADNI Meeting, Boston K-ADNI Update July 12th, 2013 Seong Yoon Kim, Seol Hee Han, Duk L. Na Update for K-ADNI, 2013 General Year1 Tasks Infrastructure setup for K-ADNI is under way. Database
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationThe Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment
The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment The Harvard community has made this article openly available.
More informationBackground. In discussions of recruitment, the question was raised as to whether returning research results to subjects would help recruitment.
Alzheimer s Disease Neuroimaging Initiative Return of Research Results Working Group The REVEAL Study NHGRI/NIA Funded d 2000-2013 2013 Background In discussions of recruitment, the question was raised
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationThe Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease
The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease AIBL: Two site collaborative study Study is conducted at two sites: Perth
More informationInternational Psychogeriatrics. Factors affecting subjective memory complaints in the AIBL ageing study: biomarkers, memory, affect and age
International Psychogeriatrics Factors affecting subjective memory complaints in the AIBL ageing study: biomarkers, memory, affect and age Journal: International Psychogeriatrics Manuscript ID: IPG-0--00.R
More informationNIH Alzheimer s Disease Centers Panel Recommendations
NIH Alzheimer s Disease Centers Panel Recommendations In June, 2017 NIA engaged leading experts from academia, industry and non-profit foundations, working in Alzheimer s and other complex diseases, in
More informationELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes
ELND005 for Agitation and Aggression in Alzheimer s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes Anton P. Porsteinsson MD 1, Susan Abushakra MD 2, Merce Boada 3, Ira Goodman 4, Giovanni
More informationCarol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia
Carol Manning, PhD, ABPP-CN Director, Memory Disorders Clinic University of Virginia Case Study Mr. S. is a 74 year old man who has smoked for 20 years. He is overweight, has high cholesterol and high
More informationNEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
More informationOn cognitive performance as endpoint in clinical trials Ben Schmand
On cognitive performance as endpoint in clinical trials Ben Schmand Department of Neurology, Academic Medical Center Department of Psychology, University of Amsterdam The Netherlands What are the best
More informationFunctional neural correlates of anosognosia in Alzheimer s disease. University Medical Center Groningen
Functional neural correlates of anosognosia in Alzheimer s disease Jaime D. Mondragón M.D., M.S. Prof. Dr. Natasha M. Maurits Prof. Dr. Peter P. De Deyn April 13 th, 2018 Department of Neurology Clinical
More informationRisk and protective factors for cognitive impairment in persons aged 85 years and older
Risk and protective factors for cognitive impairment in persons aged 85 years and older Rosebud O. Roberts, MB, ChB, MS Ruth H. Cha, MS Michelle M. Mielke, PhD Yonas E. Geda, MD, MSc Bradley F. Boeve,
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More informationIl processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D.
Il processo diagnostico dell Alzheimer dalla clinica al neuroimaging Giovanni B. Frisoni M.D. Professor of Clinical Neurosciences, University of Geneva Médecin Responsable, Memory Clinic, Hôpitaux Universitaires
More informationBehavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
Blackwell Science, LtdOxford, UKPCNPsychiatry and Clinical Neurosciences1323-13162005 Blackwell Publishing Pty Ltd593274279Original ArticleDementia and mild AlzheimersJ. Shimabukuro et al. Psychiatry and
More informationA Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework
More informationIn the past 10 years, there has been a virtual explosion in the literature concerning the construct
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. PLEASURE, MD Mild Cognitive Impairment Ten Years Later Ronald C. Petersen, PhD, MD; Rosebud O. Roberts, MB, ChB; David S. Knopman, MD; Bradley F. Boeve, MD;
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationMild cognitive impairment in Parkinson s disease: a distinct clinical entity?
Wen et al. Translational Neurodegeneration (2017) 6:24 DOI 10.1186/s40035-017-0094-4 REVIEW Mild cognitive impairment in Parkinson s disease: a distinct clinical entity? Ming-Ching Wen 1,2*, Ling Ling
More informationAGS Sleep Meeting. Marie A. Bernard, M.D. Deputy Director National Institute on Aging. October 4, 2015
AGS Sleep Meeting Marie A. Bernard, M.D. Deputy Director National Institute on Aging October 4, 2015 NIH/NIA Budget Update NIA Appropriations FY 2005-2016 PB Current versus Constant, FY05 Base Year Difference
More informationOverweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes
Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes Gordon L Jensen, MD, PhD Senior Associate Dean for Research Professor of Medicine and Nutrition Objectives Health outcomes
More informationPreventing Cognitive Decline and Dementia A Way Forward
Preventing Cognitive Decline and Dementia A Way Forward Ronald C. Petersen, PhD, MD Mayo Clinic Rochester, MN USA for Committee on Preventing Cognitive Decline National Academies of Science, Engineering
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More information9/24/2012. Amer M Burhan, MBChB, FRCP(C)
Depression and Dementia Amer M Burhan MBChB, FRCPC Head of CAMH Memory Clinic, Toronto Geriatric Neuropsychiatrist Assistant Prof Psychiatry at U of T Objectives Discuss the prevalence and impact of depression
More informationRisk Factors for Dementia and MCI in the Oldest Old The 90+ Study
Risk Factors for Dementia and MCI in the Oldest Old The 90+ Study Claudia H. Kawas, M.D. January 18, 2015 Department of Neurology Department of Neurobiology & Behavior Institute for Memory Impairment &
More informationDelirium in Older Persons: An Investigative Journey
Delirium in Older Persons: An Investigative Journey Sharon K. Inouye, M.D., M.P.H. Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Milton and Shirley F. Levy Family Chair
More information2005 Annual Report of the Center for Alzheimer s Care, Imaging & Research Department of Neurology. Center for Alzheimer s Care, Imaging and Research
2005 Annual Report of the Center for Alzheimer s Care, Imaging & Research Department of Neurology Center for Alzheimer s Care, Imaging and Research T he University of Utah Center for Alzheimer s Care,
More informationEducation M.Sc. Clinical Research Mayo Graduate School, Mayo Clinic Rochester, MN
Negash 1 Selam Negash Curriculum Vitae University of Pennsylvania Penn Memory Center 3615 Chestnut Street, Suite 310 Philadelphia, PA 19104 Email: selamawit.negash@uphs.upenn.edu Tel: (215)-349-8284 Fax:
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More information4/28/2017. Aging with Down Syndrome. Second Annual USC UCEDD Community Education Conference May 19, 2017
Aging with Down Syndrome Second Annual USC UCEDD Community Education Conference May 19, 2017 Linda D. Nelson, M.Ed., Ed.S., Ph.D., ABN Board Certified Clinical Neuropsychologist Professor, Emerita, of
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationDeveloping bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna
University of Groningen Developing bipolar disorder. A study among children of patients with bipolar disorder Hillegers, Manon Hubertine Johanna IMPORTANT NOTE: You are advised to consult the publisher's
More informationCognitive ageing and dementia: The Whitehall II Study
Cognitive ageing and dementia: The Whitehall II Study Archana SINGH-MANOUX NIH: R01AG013196; R01AG034454; R01AG056477 MRC: K013351, MR/R024227 BHF: RG/13/2/30098 H2020: #643576 #633666 Outline Lifecourse
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationConsent for Revealing Biomarker Status in AD Prevention Trials
Consent for Revealing Biomarker Status in AD Prevention Trials J. Scott Roberts, PhD Associate Professor Department of Health Behavior & Health Education University of Michigan School of Public Health
More informationPatient-centered communication, health literacy and outcomes in heart failure
Patient-centered communication, health literacy and outcomes in heart failure Matteo Fabbri MD 1, Lila J Finney Rutten Ph.D, MPH 1, Sheila M. Manemann MPH 1, Cynthia Boyd MD, MPH 3, Jennifer Wolff Ph.D
More informationPrevention, health promotion & early intervention in dementia
Prevention, health promotion & early intervention in dementia Alzheimer New Zealand Conference 2014 Steve Iliffe Professor of Primary Care & Older People University College London Rotorua, New Zealand
More informationClaims & Underwriting. You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association
Claims & Underwriting Alzheimer s & Cognitive Impairment: You already told us that story! Maria C. Carrillo, Ph.D. Sr. Director, Medical & Scientific Relations Alzheimer s Association 1 OVERVIEW Impact
More informationThe Long-term Prognosis of Delirium
The Long-term Prognosis of Jane McCusker, MD, DrPH, Professor, Epidemiology and Biostatistics, McGill University; Head, Clinical Epidemiology and Community Studies, St. Mary s Hospital, Montreal, QC. Nine
More informationPsychiatric Symptom Burden in Elders with HIV-Associated Neurocognitive Disorders
Psychiatric Symptom Burden in Elders with HIV-Associated Neurocognitive Disorders Benedetta Milanini 1, Stephanie Catella 2, Lauren Wendelken 2, Pardis Esmaeili 2, Hannah Jang 2, Robin Ketelle 2, Victor
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationOverview. Case #1 4/20/2012. Neuropsychological assessment of older adults: what, when and why?
Neuropsychological assessment of older adults: what, when and why? Benjamin Mast, Ph.D. Associate Professor & Vice Chair, Psychological & Brain Sciences Associate Clinical Professor, Family & Geriatric
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationDementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia
Dementia: A Comprehensive Update 2016 Neuroimaging, CSF, and genetic biomarkers in dementia Bradford C. Dickerson, M.D. Associate Professor of Neurology, Harvard Medical School Departments of Neurology
More informationNeuropsychiatric Predictors of Progression from Amnestic-Mild Cognitive Impairment to Alzheimer s Disease: The Role of Depression and Apathy
Journal of Alzheimer s Disease 20 (2010) 175 183 175 DOI 10.3233/JAD-2010-1352 IOS Press Neuropsychiatric Predictors of Progression from Amnestic-Mild Cognitive Impairment to Alzheimer s Disease: The Role
More informationMild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for
More informationMild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
Journal of Internal Medicine 2004; 256: 240 246 KEY SYMPOSIUM Mild cognitive impairment beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
More information